Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

284
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
284
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

498
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
498
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

740
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
740
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

277
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
277
Pneumonia IV: Management01:28

Pneumonia IV: Management

528
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
528
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.8K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical impact of mucus plugs in bronchiectasis.

Scientific reports·2026
Same author

The frequent exacerbator phenotype in bronchiectasis revisited: Data from EMBARC registry.

American journal of respiratory and critical care medicine·2026
Same author

The importance of symptoms in bronchiectasis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Gene expression profiling of whole blood samples following marathon running in non-elite athletes.

Biology of sport·2026
Same author

Mucoactive therapies and the European Respiratory Society guideline for adult bronchiectasis: what now after the CLEAR trial?

The European respiratory journal·2026
Same author

Comorbid diabetes disease severity and microbial changes in patients with bronchiectasis: a combined analysis of data from the EMBARC, EMBARC-India, Australian, and BE-China registries.

The Lancet. Respiratory medicine·2026
Same journal

Monographic Issue on New Concepts in Acute Exacerbations of COPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same journal

Radiological Approach to Severe Respiratory Infections and Pulmonary Complications in Immunocompromised Patients.

Seminars in respiratory and critical care medicine·2026
Same journal

Two Sides of the Same Smoke: Decoding Respiratory Bronchiolitis-Associated Interstitial Lung Disease and Alveolar Macrophage Pneumonia.

Seminars in respiratory and critical care medicine·2026
Same journal

Role of Vaccination in the Prevention of ECOPD.

Seminars in respiratory and critical care medicine·2026
Same journal

Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Pharmacological Treatment of AECOPD New Perspectives.

Seminars in respiratory and critical care medicine·2026
See all related articles

Related Experiment Video

Updated: Oct 28, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.2K

Long-Term Antibiotics in Bronchiectasis.

Guillermo Suarez-Cuartin1, Marta Hernandez-Argudo1, Lidia Perea2

  • 1Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Seminars in Respiratory and Critical Care Medicine
|July 14, 2021
PubMed
Summary
This summary is machine-generated.

Long-term inhaled antibiotics and oral macrolides are used for bronchiectasis management. While inhaled antibiotics improve bacterial load, their effect on quality of life is inconsistent, with bacterial load predicting response. Oral macrolides reduce exacerbations but carry risks of adverse effects and resistance.

More Related Videos

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

803
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

11.2K

Related Experiment Videos

Last Updated: Oct 28, 2025

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

23.2K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

803
P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
10:26

P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives

Published on: June 15, 2020

11.2K

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Pharmacology

Background:

  • Bronchiectasis patients often have chronic infections, leading to exacerbations and poor outcomes.
  • Current guidelines suggest long-term inhaled antibiotics and/or oral macrolides for managing bronchiectasis.
  • Evidence on the impact of these treatments on patient outcomes is growing.

Purpose of the Study:

  • To review current evidence on long-term antibiotic treatments for bronchiectasis.
  • To assess the efficacy and limitations of inhaled antibiotics and oral macrolides in bronchiectasis management.

Main Methods:

  • Systematic review of recent clinical trials and post hoc analyses.
  • Evaluation of treatment effects on sputum bacterial load, quality of life, lung function, and exacerbation rates.
  • Consideration of adverse effects and antimicrobial resistance associated with macrolides.

Main Results:

  • Inhaled antibiotics show improvements in sputum bacterial load, a potential biomarker for treatment response.
  • The impact of inhaled antibiotics on quality of life, lung function, and exacerbations is variable.
  • Oral macrolides effectively reduce exacerbation frequency and improve quality of life.
  • Concerns regarding adverse effects and increased bacterial resistance exist for oral macrolides.

Conclusions:

  • Long-term antibiotic strategies are crucial in bronchiectasis management.
  • Sputum bacterial load may guide inhaled antibiotic therapy selection.
  • Oral macrolides offer benefits but require careful monitoring due to potential risks.